Skip to content

Effects of quercetin supplement on liver fatty deposition in patients with NAFLD: a randomized, double-blind, placebo-controlled, cross-over trial

Effects of quercetin supplement on liver fatty deposition in patients with NAFLD: a randomized, double-blind, placebo-controlled, cross-over trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004988
Enrollment
Unknown
Registered
2021-06-27
Start date
2021-07-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease (NAFLD)

Interventions

Sponsors

Second Affiliated Hospital of Army Medical University, PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Resident aged 18-65 years in Chongqing; 2. No history of drinking or drinking alcohol equivalent to less than 210g/week (women 5.56%) meet the diagnostic criteria of diffuse fatty liver and no other reasons can be explained.

Exclusion criteria

Exclusion criteria: 1. Histological changes of liver biopsy within the past 6 months meet the pathological diagnostic criteria of significant or progressive fibrosis NASH or liver cirrhosis; 2. Taking lipid-lowering drugs (such as statins, fibrates, etc.) and drugs or health products that may affect liver fat content within the past 3 months (such as silibinin, ursodeoxycholic acid, bicyclol, phosphatidylcholine and vitamin E, glucocorticoids, fish oil, etc.); 3. Those with diabetes who have been treated with insulin or who have undergone bariatric surgery for obesity; 4. Patients with severe cardiac insufficiency, liver and kidney insufficiency, malignant tumor, pregnancy and lactation, or women and men who wish to become pregnant or have children during the study; 5. Patients with a history of mental illness who cannot cooperate with the research of this project; 6. There are contraindications to MRI; 7. Possible circumstances that other researchers believe would prevent completion of the study.

Design outcomes

Primary

MeasureTime frame
MRI liver proton density fat fraction;

Secondary

MeasureTime frame
fasting insulin;glycated hemoglobin;blood lipid;fasting blood sugar;liver function;renal function;

Countries

China

Contacts

Public ContactQin Yu

Second Affiliated Hospital of Army Medical University, PLA

yuer_forever@hotmail.com+86 18623198290

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026